Abstract: Objective  To observe the clinical value of serum soluble growth stimulating factor2 (sST2),  brain natriuretic peptide (BNP),  and pregnancyassociated plasma proteinA (PAPPA) in predicting adverse pregnancy outcomes in pregnancyinduced hypertension(PIH) patients with heart failure(HF). Methods  Totally 126 PIH patients with HF in our hospital were selected as PIH&HF group. PIH patients and people having pregnancy test in our hospital during the same period were selected as PIH  group (45 cases) and normal pregnancy group (45 cases),  respectively. The serum sST2,  BNP and PAPPA levels in each group were measured by enzymelinked immunosorbent assay(ELISA). The changes of serum sST2,  BNP and PAPPA levels were observed in each group,  and  their relationship with  PIH severity, HF classification,  and adverse pregnancy outcomes in patients of PIH&HF group was also analyzed,  as well astheir diagnostic efficacy in predicting adverse pregnancy outcomes. Results  The serum levels of sST2,  BNP and PAPPA in PIH&HF group were significantly higher than those in PIH group and normal pregnancy group (P<0.01),  while the levels in PIH group were significantly higher than those in normal pregnancy group (P<0.01).The serum sST2,  BNP and PAPPA levels in PIH&HF group increased as the rise of PIH  severity and cardiac function (P<0.01). The serum sST2,  BNP,  and PAPPA levels in PIH&HF group were significantly higher in adverse pregnancy outcomes group than those in good pregnancy outcomes group (P<0.01). Conclusion  The serum sST2,  BNP and PAPPA levels are related to the severity of PIH with HF,  and have high efficacy and important clinical value in predicting adverse pregnancy outcomes.

Key words: hypertension, pregnancyinduced, intercellular signaling peptides and proteins, natriuretic peptide, brain, pregnancyassociated plasma proteinA, pregnancyinduced hypertension, heart failure, congestive; , pregnancy outcome